Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics insider Todd Edwards filed a notice to sell 2,052 shares of common stock under Rule 144. The planned sale, through Merrill on NASDAQ, has an aggregate market value of $52,322.72 and an approximate sale date of February 2, 2026.
The shares to be sold were acquired as restricted stock that vested on February 1, 2026 from Arcutis Biotherapeutics Inc. The filing also reports that Edwards sold 29,131 common shares on November 6, 2025 for gross proceeds of $732,051.95 during the prior three months.
A shareholder of Arcutis Biotherapeutics plans to sell 1,320 common shares under Rule 144. The shares have an aggregate market value of $33,657.89, with Arcutis having 122,492,192 shares outstanding. The sale, through Merrill Lynch on NASDAQ, is expected around February 2, 2026.
The seller acquired the 1,320 shares on February 1, 2026 via restricted stock vesting from Arcutis Biotherapeutics, with payment on the same date. Over the prior three months, the same person sold 88 common shares on November 3, 2025 for gross proceeds of $2,155.
Arcutis Biotherapeutics insider schedules sale of restricted shares under Rule 144. A holder has filed to sell 3,675 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on or about 02/02/2026 on the NASDAQ, with an aggregate market value listed at $93,706.62.
These shares were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The notice also lists several prior sales of Arcutis common stock by Patrick Burnett during the past three months, each with specified dates, share amounts, and gross proceeds.
Arcutis Biotherapeutics insider activity: A holder has filed to sell 19,833 shares of Arcutis Biotherapeutics common stock under Rule 144 through Merrill on the NASDAQ, with an approximate sale date of 02/02/2026. The filing notes 122,492,192 common shares outstanding for this class.
The 19,833 shares were acquired on 02/01/2026 via a restricted stock vest from Arcutis Biotherapeutics, Inc., with payment also dated 02/01/2026. In the prior three months, Todd F. Watanabe reported sales of 48,945 and 1,055 common shares, with gross proceeds of 1,485,759 and 31,650, respectively.
Arcutis Biotherapeutics insider Howard Welgus filed a Rule 144 notice to sell 10,000 shares of common stock through Merrill, with an aggregate market value of $250,482.69. The shares relate to a stock option exercise on 06/04/2018, paid in cash.
Welgus reports prior sales over the past three months of 10,000 shares each on 11/03/2025, 12/01/2025, and 01/02/2026, with gross proceeds of $252,668.51, $302,133.02, and $289,606.03. The planned sale is expected around 02/02/2026 on NASDAQ, where 122,492,192 shares of the issuer’s common stock are outstanding.
Jennison Associates LLC reports beneficial ownership of 6,758,006 shares of Arcutis Biotherapeutics Inc. common stock, representing 5.5% of the outstanding class as of 12/31/2025. Jennison has sole power to vote these shares and shared power to dispose of them.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Arcutis. The filing is signed by a Senior Vice President, Compliance, on behalf of Jennison Associates LLC.
Arcutis Biotherapeutics, Inc. Executive Vice President and Chief Medical Officer Patrick Burnett reported a planned sale of company stock. On January 5, 2026, he sold 2,490 shares of Arcutis common stock at a weighted average price of $28.9822 per share under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After this transaction, he beneficially owned 94,120 shares of Arcutis common stock directly.
Arcutis Biotherapeutics, Inc. director Howard G. Welgus reported selling 10,000 shares of common stock on 01/02/2026 at a weighted average price of $28.9606 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026.
After this planned sale, Welgus beneficially owned 69,744 shares of Arcutis common stock directly. The shares were sold in multiple transactions at prices ranging from $28.905 to $29.17 per share.
Arcutis Biotherapeutics Executive Vice President and Chief Medical Officer Patrick Burnett reported an option exercise and share sale in Arcutis Biotherapeutics, Inc. common stock. On 12/15/2025, he exercised a stock option for 11,500 shares at an exercise price of $3.64 per share, then sold 11,500 shares on the same date at a weighted average price of $28.9436 per share under transaction code S.
These trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/12/2024, with a plan end date of 02/27/2026. After the transactions, Burnett beneficially owned 98,307 shares of common stock directly and 143,750 stock options. The report also corrects a prior overstatement of his beneficial ownership by 18 shares due to a scrivener's error.
Arcutis Biotherapeutics announced changes to its board leadership and a new consulting role for a retiring director. Bhaskar Chaudhuri retired from the board and as chair of the Compensation Committee on December 3, 2025, and entered into a transition and consulting agreement under which he will hold the honorary title of Founder and Director Emeritus and provide strategic advisory support through June 30, 2027. During this period, his existing stock options and restricted stock units will continue to vest, and he may exercise vested options, with a three-month post-termination exercise window.
On December 4, 2025, the board appointed Amit D. Munshi as a new Class II director and chair of the Compensation Committee, with a term running until the 2028 annual meeting of stockholders, subject to earlier departure events. As a non-employee director, he received an initial stock option grant for 16,502 shares of common stock and is eligible for a prorated annual equity award valued at approximately $300,000, allocated 65% to stock options and 35% to restricted stock units, plus prorated annual cash retainers of $50,000 for board service and $15,000 for chairing the Compensation Committee.